Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Plus Sintilimab for HCC with PVTT
NCT04104074Phase 1Unknown
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sintilimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Incidence of treatment-emergent adverse events at 1 year. Status: unknown.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04104074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104074.